This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n16http://linked.opendata.cz/resource/domain/vavai/subjekt/
n9http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61383082%3A_____%2F11%3A0070%21RIV12-MO0-61383082/
n6http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n18http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61383082%3A_____%2F11%3A0070%21RIV12-MO0-61383082
rdf:type
n6:Vysledek skos:Concept
dcterms:description
All patients in this open-label multinational study were assigned at the investigator'sdiscretion to receive peginterferon α-2a (40 KD) 180 µg/week plus ribavirin (800 mg/day) for a total of 24 weeks or peginterferon α-2a (40 KD) 180 µg/week plus ribavirin (1000/1200 mg/day) for a total of 48 weeks. Treatment success was defined as sustained virological response [sustained virological response (SVR); hepatitis C virus RNA less than 50 IU/ml after completion of untreated follow-up]. The combination of peginterferon α-2a (40 KD) plus ribavirin was well tolerated and produced an overall SVR rate of 58% in treatment-naive patients. This study confirms that SVR rates achieved in pivotal clinical trials in Western Europe and the USA can be achieved in routine clinical practice in Central and Eastern Europe. All patients in this open-label multinational study were assigned at the investigator'sdiscretion to receive peginterferon α-2a (40 KD) 180 µg/week plus ribavirin (800 mg/day) for a total of 24 weeks or peginterferon α-2a (40 KD) 180 µg/week plus ribavirin (1000/1200 mg/day) for a total of 48 weeks. Treatment success was defined as sustained virological response [sustained virological response (SVR); hepatitis C virus RNA less than 50 IU/ml after completion of untreated follow-up]. The combination of peginterferon α-2a (40 KD) plus ribavirin was well tolerated and produced an overall SVR rate of 58% in treatment-naive patients. This study confirms that SVR rates achieved in pivotal clinical trials in Western Europe and the USA can be achieved in routine clinical practice in Central and Eastern Europe.
dcterms:title
%22Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe %22Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe
skos:prefLabel
%22Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe %22Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe
skos:notation
RIV/61383082:_____/11:0070!RIV12-MO0-61383082
n6:predkladatel
n16:ico%3A61383082
n3:aktivita
n7:V n7:S
n3:aktivity
S, V
n3:cisloPeriodika
11
n3:dodaniDat
n11:2012
n3:domaciTvurceVysledku
n4:6699243
n3:druhVysledku
n13:J
n3:duvernostUdaju
n12:S
n3:entitaPredkladatele
n9:predkladatel
n3:idSjednocenehoVysledku
196704
n3:idVysledku
RIV/61383082:_____/11:0070
n3:jazykVysledku
n15:eng
n3:klicovaSlova
Hepatitis C; pegylated interferon; ribavirin; sustained virological response
n3:klicoveSlovo
n10:pegylated%20interferon n10:sustained%20virological%20response n10:ribavirin n10:Hepatitis%20C
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[0E0BF2B37CC3]
n3:nazevZdroje
European journal of gastroenterology & hepatology 2011
n3:obor
n17:FE
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
7
n3:rokUplatneniVysledku
n11:2011
n3:svazekPeriodika
23
n3:tvurceVysledku
Urbánek, Petr Messinger, D. Ivanovski, L. Oltman, M. Rehák, V. Husa, P. Tietz, A.
s:issn
0954-691X
s:numberOfPages
7
n18:doi
10.1097/MEG.0b013e32834b326b